SIC
MLTX icon

SJS Investment Consulting’s MoonLake Immunotherapeutics MLTX Stock Holding History

SJS Investment Consulting’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.05K Buy
+54
New +$979 ﹤0.01% 2014

Other funds holding MLTX

CFM
Capricorn Fund Managers London, United Kingdom $1.27B AUM 70.17% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
S
SignatureFD Atlanta, Georgia $7.49B AUM 24.82% 1-Year Est. Return
EWA
EverSource Wealth Advisors Birmingham, Alabama $2.97B AUM 28.74% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $420M AUM 22.7% 1-Year Est. Return

SJS Investment Consulting's MLTX Position: Q2 2026 in Review

SJS Investment Consulting opened a new position in MoonLake Immunotherapeutics (MLTX) in Q2 2026: 54 shares worth $1.05K. The stake represents ﹤0.01% of the portfolio and ranks #2014 among its holdings.

14 funds tracked by Wall St. Rank hold MLTX as of Q2 2026.

  • SJS Investment Consulting held 54 shares of MoonLake Immunotherapeutics worth $1.05K as of Q2 2026.
  • MoonLake Immunotherapeutics was a new SJS Investment Consulting position in Q2 2026.
  • MoonLake Immunotherapeutics made up ﹤0.01% of SJS Investment Consulting's portfolio in Q2 2026, its #2014 holding.
  • 14 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q2 2026.

Based on SJS Investment Consulting's 13F filing for Q2 2026, filed 22 Jul 2026.